MABS 03
Alternative Names: MABS-03Latest Information Update: 29 Jan 2025
Price :
$50 *
At a glance
- Originator Manhattan BioSolutions
- Class Antibodies; Antineoplastics; Drug conjugates; Immunoconjugates
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Solid tumours
Most Recent Events
- 23 Jan 2025 Early research in Solid tumours in USA (Parenteral), before January 2025 (Manhattan BioSolutions pipeline, January 2025)